Nagasaki University:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Nagasaki University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9284
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Nagasaki University is an educational service provider that operates graduate schools, undergraduate schools, and research institutes. The university offers under graduate level education in the fields of economics, dentistry, pharmaceutical sciences, medicine, environmental studies, engineering, and fisheries, among others. It also provides master’s degree, bachelor’s degrees, and doctoral degree programs, among others. Nagasaki University’s faculty of education includes departments such as education and psychology, natural science, intercultural studies, art expression, elementary education, teaching skills development and practice, life health, and teacher training and practice, among others. The university offers its services to students from across the world. Nagasaki University is headquartered in Nagasaki, Japan.

Nagasaki University – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Nagasaki University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nagasaki University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Nagasaki University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nagasaki University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Nagasaki University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Nagasaki University, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
VLP Therapeutics Enters into Research Agreement with Nagasaki University 10
Shin Nippon Biomedical Labs Enters Into Research Agreement With Nagasaki University 11
Shin Nippon Biomedical Labs Enters Into Research Agreement With Nagasaki University For Cerebral Infarction Treatment 12
Nagasaki University Enters Into Research Agreement With Astellas Pharma To Discover New Drugs For NTDs 13
Nagasaki University – Key Competitors 14
Nagasaki University – Key Employees 15
Nagasaki University – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Government and Public Interest 18
Sep 26, 2017: Discovering potential therapeutic protein inhibitors for Chagas disease 18
Other Significant Developments 19
Mar 28, 2018: As the GHIT Fund Closes Out First Five Years of R&D for Lifesaving Medical Breakthroughs, It Launches Next Phase, Focusing on Access and Delivery, Bringing Total Investment to 13.2 Billion Yen (US$123 Million) 19
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Nagasaki University, Pharmaceuticals & Healthcare, Key Facts 2
Nagasaki University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nagasaki University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Nagasaki University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nagasaki University, Deals By Therapy Area, 2012 to YTD 2018 8
Nagasaki University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
VLP Therapeutics Enters into Research Agreement with Nagasaki University 10
Shin Nippon Biomedical Labs Enters Into Research Agreement With Nagasaki University 11
Shin Nippon Biomedical Labs Enters Into Research Agreement With Nagasaki University For Cerebral Infarction Treatment 12
Nagasaki University Enters Into Research Agreement With Astellas Pharma To Discover New Drugs For NTDs 13
Nagasaki University, Key Competitors 14
Nagasaki University, Key Employees 15
Nagasaki University, Subsidiaries 17

List of Figures
Nagasaki University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Nagasaki University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Nagasaki University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Nagasaki University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Nagasaki University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nagasaki University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Nagasaki University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nagasaki University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Nagasaki University:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Natera Inc (NTRA):企業の財務・戦略的SWOT分析
    Summary Natera Inc (Natera), formerly Gene Security Network Inc is a genetic testing and diagnostics company that develops and commercializes non-invasive methods for DNA analysis. The company offers products such as panorama prenatal testing, pre-implantation genetic testing, miscarriage testing, g …
  • SOGAZ Insurance Group:企業の戦略・SWOT・財務分析
    SOGAZ Insurance Group - Strategy, SWOT and Corporate Finance Report Summary SOGAZ Insurance Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Pentair plc (PNR)-石油・ガス分野:企業M&A・提携分析
    Summary Pentair plc (Pentair) is an industrial manufacturing company. It designs, manufactures and markets water system products and solutions for filtration, separation and fluid process management; and products that guard sensitive electrical and electronic equipment; and heat management solutions …
  • EOS imaging SA (EOSI):医療機器:M&Aディール及び事業提携情報
    Summary EOS imaging SA (EOS Imaging) is an orthopedic imaging company that designs, develops, and markets EOS patented medical imaging system. EOS captures whole body images of a standing patient in a single scan without any stitching or vertical distortion. Through EOS, the company provides the ful …
  • Occidental Petroleum Corporation (OXY)-エネルギー分野:企業M&A・提携分析
    Summary Occidental Petroleum Corporation (Occidental) is an oil and gas exploration and production company with integrated assets. The company is active in upstream exploration and production; midstream and marketing; and chemicals business. The oil and gas business explores for, develops and produc …
  • Compagnie Financiere Richemont SA:企業の戦略・SWOT・財務情報
    Compagnie Financiere Richemont SA - Strategy, SWOT and Corporate Finance Report Summary Compagnie Financiere Richemont SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • BELLUS Health Inc (BLU):製薬・医療:M&Aディール及び事業提携情報
    Summary BELLUS Health Inc (BELLUS Health) is a biopharmaceutical development company, which focuses on developing drugs for rare diseases. The company’s pipeline products include BLU-5937 for chronic cough, Shigamab for STEC related hemolytic syndrome (sHUS); KIACTA for the treatment of a second ind …
  • Repsol SA (REP):企業の財務・戦略的SWOT分析
    Repsol SA (REP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • New York & Company, Inc.:企業の戦略・SWOT・財務情報
    New York & Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary New York & Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • BioClin Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary BioClin Therapeutics Inc (BioClin) is a clinical stage biotechnology company developing protein therapeutics for genetic disorders. Its lead product candidate B-701 is a human monoclonal antibody which targets the activity of FGFR3 (fibroblast growth factor receptor 3) and does not interact …
  • Columbus McKinnon Corp (CMCO):企業の財務・戦略的SWOT分析
    Summary Columbus McKinnon Corp (CMCO) is an industrial equipment company that offers cranes and hoists. The company designs, manufactures and markets material handling systems and services, which are used for moving, lifting, positioning and securing materials. Its products include hoists, actuators …
  • Gujarat State Petroleum Corp Ltd:企業の戦略的SWOT分析
    Gujarat State Petroleum Corp Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Albireo Pharma Inc (ALBO)-製薬・医療分野:企業M&A・提携分析
    Summary Albireo Pharma Inc (Albireo), formerly Biodel Inc., is a specialty biopharmaceutical company that focuses on the development and commercialization of innovative bile acid modulators for the treatment of orphan pediatric liver diseases and other liver and gastrointestinal (GI) disorders and d …
  • Option NV (OPTI):企業の財務・戦略的SWOT分析
    Option NV (OPTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Providence Resources plc (PZQA):企業の財務・戦略的SWOT分析
    Summary Providence Resources Plc (Providence Resource) is an upstream oil and gas exploration and development company that explores and develops hydrocarbon assets. The company's areas of operations include Northern Porcupine basin, Southern Porcupine basin, Goban Spur basin, Saint George's basin an …
  • HDR Inc:企業の戦略的SWOT分析
    HDR Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Birks Group Inc (BGI):企業の財務・戦略的SWOT分析
    Birks Group Inc (BGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Carlsberg AS (CARL B):企業の財務・戦略的SWOT分析
    Carlsberg AS (CARL B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • NRG Energy Inc (NRG):企業の財務・戦略的SWOT分析
    NRG Energy Inc (NRG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Nintendo Co Ltd (7974):企業の財務・戦略的SWOT分析
    Nintendo Co Ltd (7974) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆